

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5685884

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MEDIMMUNE, LLC	10/24/2017
RECEIVING PARTY DATA		
Name:	MEDIMMUNE LIMITED	
Street Address:	MILSTEIN BUILDING	
Internal Address:	GRANTA PARK	
City:	CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB21 6GH	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16400818
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	312-474-6300	
Email:	docket@marshallip.com, tsevcik@marshallip.com	
Correspondent Name:	KATHERINE L. NEVILLE	
Address Line 1:	233 S. WACKER DRIVE	
Address Line 2:	SUITE 6300	
Address Line 4:	CHICAGO, ILLINOIS 60606	
ATTORNEY DOCKET NUMBER:	33056/50003B	
NAME OF SUBMITTER:	KATHERINE L. NEVILLE	
SIGNATURE:	/KATHERINE L. NEVILLE/	
DATE SIGNED:	08/26/2019	
Total Attachments: 3		
source=50003B_MedImmune_LLC_to_MedImmune_Limited_Assignment#page1.tif		
source=50003B_MedImmune_LLC_to_MedImmune_Limited_Assignment#page2.tif		
source=50003B_MedImmune_LLC_to_MedImmune_Limited_Assignment#page3.tif		

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 24 day of October 2017 (the "Effective Date") by and between

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware, whose post office address is One Medimmune Way, Gaithersburg, Maryland 20878, the United States of America ("Assignor"); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales whose registered office is Millstein Building, Granta Park, Cambridge CB21 6GH United Kingdom ("Assignee").


WHEREAS, Assignor has agreed to assign to Assignee the Assignor's entire right, title and interest in and to the patent applications identified in the attached Schedule (the "Applications") and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of payments made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their legal right, legal title and legal interest in and to the inventions, the Application and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Application and any patents or applications derived therefrom; and the right to file patent applications derived from the Application directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.




Signed for and on behalf of
MedImmune, LLC



Name: Mita Mukherjee

Title: Authorised Signatory

Date: October 24, 2017



Witnessed by




Signed for and on behalf of
MedImmune Limited


Name: Chris Winter

Title: Authorised Signatory

Date: 26 October 2017



Witnessed by



THE SCHEDULE

APPLICATIONS					
AstraZeneca Case No:	Country	Application No.	Filing Date	Grant No.	Grant Date
PSEUD-100-AU-PCD	Australia	2017204447	29 Jun 2017		
PSEUD-100-BR-PCT	Brazil	BR112013031485-0	06 Dec 2013		
PSEUD-100-CA-PCI	Canada	2,838,211	03 Dec 2013		
PSEUD-100-CN-PCT	China	201280028257.7	09 Dec 2013		
PSEUD-100-EP-EPT	European Procedure (Patents)	12796646.3	10 Jan 2014		
PSEUD-100-HK-FPR	Hong Kong	14110227.8	14 Oct 2014		
PSEUD-100-ID-PCT	Indonesia	P-00201400103	08 Jan 2014	IDP000044809	01 Mar 2017
PSEUD-100-WO-PCT	International Procedure	PCT/US2012/041538	08 Jun 2012		
PSEUD-100-JP-PCD	Japan	2016-237276	06 Dec 2016		
PSEUD-100-JP-PCT	Japan	2014-514881	09 Dec 2013	6058645	16 Dec 2016
PSEUD-100-MX-PCT	Mexico	MX/a/2013/014372	06 Dec 2013	349886	17 Aug 2017
PSEUD-100-NZ-PCT	New Zealand	618266	27 Nov 2013	618266	02 Aug 2016
PSEUD-100-RU-PCT	Russian Federation	2014100111	09 Jan 2014		
PSEUD-100-KR-PCT	South Korea / Republic of Korea	10-2013-7035124	31 Dec 2013		
PSEUD-100-US-PCD	United States Of America	15/192,072	24 Jun 2016		
PSEUD-100-US-PCI	United States Of America	14/125,073	22 Apr 2014	9,403,901	02 Aug 2016